debate: should dlbcl patients be treated differently based on cell of origin? - no
Published 9 years ago • 538 plays • Length 9:30Download video MP4
Download video MP3
Similar videos
-
12:05
debate: should dlbcl patients be treated differently based on cell of origin? - yes
-
20:02
what are the hurdles to using cell of origin in classification to treat dlbcl?
-
15:16
debate: how should patients with abc type dlbcl be treated today? - r-chop
-
20:48
current upfront management of dlbcl
-
24:24
double-hit dlbcl
-
6:35
high grade diffuse large b-cell lymphoma: carole's story
-
46:48
relapsed and refractory diffuse large b-cell lymphoma
-
9:16
understanding diffuse large b-cell lymphoma
-
13:46
debate: should we do surveillance imaging for dlbcl patients in remission? - yes
-
20:11
should we use cell of origin and "double protein" expression in treating dlbcl?
-
11:22
debate: follicular lymphoma - do not treat
-
21:37
how i approach upfront and relapsed dlbcl
-
20:10
lymphomas in 2024 changing standards of care and challenging paradigms elizabeth brem, md from uci
-
33:05
debate: watch and wait in follicular lymphoma: should we treat immediately?
-
30:05
who should get what for upfront therapy for mantle cell lymphoma?
-
16:04
debate: is maintenance therapy of value following frontline treatment for advanced dlbcl - no
-
9:09
debate: is maintenance therapy of value following frontline treatment for advanced dlbcl - yes
-
9:21
debate: a case of stage i follicular lymphoma - radiation /- systemic treatment
-
17:19
debate: should young patients with mantle cell lymphoma be treated aggressively? - yes
-
16:21
should r-chop remain the standard of care for dlbcl?
-
25:57
what is the best approach to limited stage dlbcl? do we need radiation?
-
21:26
polatuzumab fda approval in dlbcl (polarix) & swog s1826 nivo vs. bv in hodgkin's lymphoma